BLOCK-SAH研究原理与设计:翼腭窝阻滞作为动脉瘤性蛛网膜下腔出血急性头痛的阿片节约治疗——一项采用序贯平行比较设计的II期、多中心、随机、双盲、安慰剂对照临床试验
动脉瘤性蛛网膜下腔出血后急性头痛常见且严重,治疗手段有限且高度依赖阿片类药物,总体疼痛控制不佳。BLOCK-SAH是一项II期、多中心、随机、双盲、安慰剂对照试验,采用序贯平行比较设计,随后进入开放标签阶段,计划在美国12个中心随机195例觉醒、因重度头痛需阿片类药物且能口头表达疼痛评分的动脉瘤性蛛网膜下腔出血患者。参与者分三组接受连续2天双侧活性或安慰剂翼腭窝注射,活性注射为5 mL含20 mg罗哌卡因加4 mg地塞米松,安慰剂为生理盐水,均在超声引导下进行,并用经颅多普勒监测围手术期颅内动脉平均血流速度。主要疗效终点为每次翼腭窝注射后24小时内口服吗啡当量日用量,主要安全终点为首 次注射后48小时影像学血管痉挛发生率,主要耐受性终点为首次注射后第二次注射的接受率。
要点
- BLOCK-SAH计划在美国12个中心随机195例动脉瘤性蛛网膜下腔出血后需阿片类药物的重度头痛患者,采用序贯平行比较设计。
- 活性翼腭窝阻滞为超声引导下双侧注射5 mL含20 mg罗哌卡因加4 mg地塞米松,安慰剂为生理盐水。
- 主要疗效终点为每次注射后24小时内口服吗啡当量日用量,主要安全终点为首次注射后48小时影像学血管痉挛发生率。
- 主要耐受性终点为首次翼腭窝注射后第二次注射的接受率。
- 围手术期用经颅多普勒监测颅内动脉平均血流速度。
适用人群与场景
- 动脉瘤性蛛网膜下腔出血后出现重度头痛、需要阿片类药物控制疼痛且能口头表达疼痛评分的觉醒患者。
处置流程与药物剂量
- 在超声引导下进行双侧翼腭窝注射,连续2天;活性阻滞注射剂为5 mL含20 mg罗哌卡因加4 mg地塞米松,安慰剂注射为生理盐水。
- 围手术期使用经颅多普勒监测颅内动脉平均血流速度。
- 按序贯平行比较设计分为三组:第1组先活性阻滞后安慰剂,第2组先安慰剂后活性阻滞,第3组先安慰剂后安慰剂。
研究设计与关键结果
- BLOCK-SAH为II期、多中心、随机、双盲、安慰剂对照临床试验,采用序贯平行比较设计,随后进入开放标签阶段。
- 计划在美国12个中心随机195例合格参与者,分为三组接受连续2天双侧活性或安慰剂翼腭窝注射。
- 主要疗效终点为每次翼腭窝注射后24小时内口服吗啡当量日用量;主要安全终点为首次翼腭窝注射后48小时影像学血管痉挛发生率;主要耐受性终点为首次注射后第二次注射的接受率。
证据类型、等级与局限
- 证据类型:II期、多中心、随机、双盲、安慰剂对照临床试验的设计方案。
- 局限:原文未报告局限性。
对床旁实践的改变
- BLOCK-SAH试验将指导III期试验的设计,以确立翼腭窝阻滞的疗效,并考虑不同的头痛表型。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute post-subarachnoid hemorrhage (SAH) headaches are common and severe. Management strategies for post-SAH headaches are limited, with heavy reliance on opioids, and pain control is overall poor. Pterygopalatine fossa (PPF) nerve blocks have shown promising results in treatment of acute headache, including our preliminary and published experience with PPF-blocks for refractory post-SAH headache during hospitalization. The BLOCK-SAH trial was designed to assess the efficacy and safety of bilateral PPF-blocks in awake patients with severe headaches from aneurysmal SAH who require opioids for pain control and are able to verbalize pain scores.
METHODS: BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial using the sequential parallel comparison design (SPCD), followed by an open-label phase.
RESULTS: Across 12 sites in the United States, 195 eligible study participants will be randomized into three groups to receive bilateral active or placebo PPF-injections for 2 consecutive days with periprocedural monitoring of intracranial arterial mean flow velocities with transcranial Doppler, according to SPCD (group 1: active block followed by placebo; group 2: placebo followed by active block; group 3: placebo followed by placebo). PPF-injections will be delivered under ultrasound guidance and will comprise 5-mL injectates of 20 mg of ropivacaine plus 4 mg of dexamethasone (active PPF-block) or saline solution (placebo PPF-injection).
CONCLUSIONS: The trial has a primary efficacy end point (oral morphine equivalent/day use within 24 h after each PPF-injection), a primary safety end point (incidence of radiographic vasospasm at 48 h from first PPF-injection), and a primary tolerability end point (rate of acceptance of second PPF-injection following the first PPF-injection). BLOCK-SAH will inform the design of a phase III trial to establish the efficacy of PPF-block, accounting for different headache phenotypes.
参考来源
- Busl KM, Smith CR, Troxel AB, et al. Rationale and Design for the BLOCK-SAH Study (Pterygopalatine Fossa Block as an Opioid-Sparing Treatment for Acute Headache in Aneurysmal Subarachnoid Hemorrhage): A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial with a Sequential Parallel Comparison Design. Neurocrit Care. 2024. PMID: 39138719. doi:10.1007/s12028-024-02078-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。